United Therapeutics (UTHR) Form 4 Filings

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options for common stock at an exercise price of $135.42 per share and acquired an equal number of shares on August 26, 2026. Those 9,500 shares were then sold the same day in multiple open-market transactions by a family trust at weighted-average prices in the $514–$521 range, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the option exercise, a family trust continued to hold 56,410 stock options expiring March 15, 2027, and separate entries show direct ownership of 40,513 UTHR shares and additional indirect holdings, including 166 shares held by a spouse.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options for common stock at an exercise price of $135.42 per share and acquired 9,500 common shares on August 25, 2026. The same day, those 9,500 indirectly held shares were sold in multiple open-market transactions at weighted average prices between $515.46 and $520.52 per share. After the option exercise, a family trust held 65,910 stock options, and separately, Rothblatt held 40,513 common shares directly and 166 shares indirectly through a spouse. These option exercises and related sales were made under a Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027, or December 31, 2026.

UNITED THERAPEUTICS Corp (UTHR) reported that family trusts associated with Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share into common stock and sold 9,500 common shares on August 24, 2026 in multiple trades at weighted-average prices around $509–$513 per share. The options transaction reduced the trust’s stock option position to 75,410 options. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 options expiring March 15, 2027 or December 31, 2026. Separately, Rothblatt reports 40,513 UTHR common shares held directly and 166 shares held indirectly by spouse.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share and acquired 9,500 shares of common stock on August 21, 2026. On the same date, those 9,500 common shares were sold in multiple trades at weighted-average prices, with individual trades executed in ranges from $512.51 to $528.02 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the option exercise, a family trust held 84,910 stock options, while reported direct common stock holdings were 40,513 shares, with additional indirect holdings by spouse and family trusts.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at $135.42 per share into common stock and sold 9,500 common shares on August 20, 2026 at weighted average prices around $518–$525. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the option exercise, the trust holds 94,410 stock options from this grant, while Rothblatt also reports 40,513 common shares held directly and 166 shares held indirectly by spouse, with additional indirect holdings in family trusts.

UNITED THERAPEUTICS Corp (UTHR) reported that EVP & General Counsel Paul A. Mahon exercised stock options for 8,300 shares of common stock at an exercise price of $146.03 per share on August 20, 2026, and sold 8,300 shares in multiple open-market trades at prices between approximately $520.03 and $527.21. The options exercise and resulting share sales were carried out under a pre-arranged Rule 10b5-1 plan entered into on August 11, 2025.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share, receiving 9,500 shares of common stock, and on the same date sold 9,500 shares in multiple open-market transactions at prices around $522–$536 per share.

After the option exercise, a family trust held 103,910 stock options. Additional holdings reported include 40,513 shares held directly and 166 shares held indirectly by spouse. All option exercises and related sales were made under a Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 stock options expiring March 15, 2027, or December 31, 2026.

UNITED THERAPEUTICS Corp (UTHR) Chairperson & CEO Martine Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share into 9,500 shares of common stock on August 18, 2026, then sold 9,500 shares in multiple open-market trades at weighted average prices around the low-$500s per share. After the option exercise, the family trust held 113,410 stock options, and Rothblatt also reported 40,513 shares held directly and 166 shares held indirectly by spouse. All option exercises and related sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which covers up to 1,734,410 options expiring March 15, 2027, or runs until December 31, 2026.

UNITED THERAPEUTICS Corp (UTHR) reported insider activity by Chairperson & CEO Martine A. Rothblatt involving option exercises and related sales executed through family trusts. A family trust exercised 9,500 stock options at an exercise price of $135.42 per share, converting them into 9,500 shares of common stock held indirectly.

On the same date, the trust sold a total of 9,500 common shares in multiple open-market transactions at weighted average prices ranging from about $501.06 to $508.17 per share. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027, or December 31, 2026. Following the derivative transaction, a family trust continues to hold 122,910 stock options, while reported common stock holdings include 40,513 shares held directly by Rothblatt and 166 shares held indirectly by a spouse, plus additional indirect trust holdings.

UNITED THERAPEUTICS Corp’s Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share into 9,500 shares of common stock, then sold 9,500 shares on August 14, 2026 in multiple open‑market trades at weighted‑average prices between about $494.61 and $501.14. The filing reports 132,410 stock options remaining in a family trust after this exercise, and direct holdings of 40,513 common shares plus 166 shares held indirectly by a spouse. These transactions were made under a pre‑arranged 10b5-1 trading plan adopted November 7, 2025, which continues until either the exercise of 1,734,410 options expiring March 15, 2027 or December 31, 2026.

UNITED THERAPEUTICS Chairperson & CEO Martine A. Rothblatt reported an option exercise and related stock sales for family trusts. On 2026-08-13, a family trust exercised 9,500 stock options at an exercise price of $135.42 per share, receiving 9,500 shares of common stock indirectly. The trust then sold 9,500 shares in multiple trades at weighted-average prices generally around $500–$513 per share. Following the option exercise, the trust continues to hold 141,910 stock options expiring on March 15, 2027. Separately, Rothblatt holds 40,513 shares directly and 166 shares indirectly through a spouse. The option exercise and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of exercising 1,734,410 options expiring March 15, 2027 or December 31, 2026.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 and acquired an equal number of common shares on 2026-08-12. The trust then sold 9,500 common shares in multiple trades at weighted-average prices around $507–$521 per share pursuant to a pre-arranged Rule 10b5-1 trading plan. After the option exercise, the family trust held 151,410 stock options with a March 15, 2027 expiration, while Rothblatt also reported 40,513 directly held common shares and 166 shares held indirectly by a spouse.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share into common stock on 2026-08-11, then sold 9,500 common shares in multiple trades at prices reported between roughly $512.94 and $531.29 per share. The option exercise and related sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which covers up to 1,734,410 stock options expiring March 15, 2027 and is scheduled to continue until the earlier of that full exercise or December 31, 2026. Following the option transaction, a family trust associated with the reporting person held 160,910 stock options, and reported direct common stock holdings were 40,513 shares, with an additional 166 shares held indirectly by spouse and further shares held in various family trusts.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share on August 10, 2026, acquiring 9,500 shares of common stock. On the same date, those 9,500 common shares were sold in multiple open-market transactions at prices generally in the $523–$539 per-share range. Following the option exercise, the trust continues to hold 170,410 stock options with an expiration date of March 15, 2027. The activity was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which remains in effect until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027, or December 31, 2026. Separately, Rothblatt reports direct ownership of 40,513 common shares and indirect ownership of 166 common shares held by a spouse, with additional indirect holdings in family trusts.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options into common stock at an exercise price of $135.42 per share and on August 7, 2026 sold 9,500 common shares in multiple transactions at per-share prices reported between roughly $525 and $540. The options transaction left 179,910 stock options held by the trust. These trades were made under a Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027 or December 31, 2026. Reported holdings also include 40,513 shares held directly and 166 shares held indirectly by spouse.

United Therapeutics Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised stock options for 9,500 shares at an exercise price of $135.42 on August 6, 2026, then sold the resulting 9,500 common shares in multiple indirect transactions at per-share prices including $512.5000 and $532.3932.

These option exercises and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 options expiring March 15, 2027 or December 31, 2026; 189,410 options remain held by the family trust, alongside direct and other indirect share holdings.

United Therapeutics Corp executive Paul A. Mahon exercised stock options for 8,300 shares of common stock at $146.03 per share, then sold 8,300 shares in several trades on August 6, 2026, at weighted‑average prices per share including $512.9174 and $521.4972. After the exercise he held 72,440 stock options. The transactions were executed under a pre‑arranged Rule 10b5‑1 trading plan entered into on August 11, 2025.

United Therapeutics Chairperson & CEO Martine A. Rothblatt, via a family trust, exercised 9,500 stock options at $135.42 per share into common stock and sold 9,500 shares in multiple trades on August 5, 2026. These transactions were made under a pre-arranged 10b5-1 trading plan adopted November 7, 2025, which contemplates exercising up to 1,734,410 options expiring March 15, 2027. Following this exercise, a family trust continues to hold 198,910 stock options, and Rothblatt also reports 40,513 common shares held directly, in addition to other indirect holdings through family trusts.

United Therapeutics chairperson and CEO Martine A. Rothblatt, indirectly through family trusts, exercised 9,500 stock options at $135.4200 per share on August 4, 2026 and received an equal number of common shares.

On the same date those 9,500 shares were sold in multiple tranches at reported weighted average prices such as $512.4859, $516.5935 and $517.4960 per share, under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025.

The plan continues until the earlier of exercising up to 1,734,410 stock options expiring March 15, 2027 or December 31, 2026; 208,410 stock options remain held indirectly in a family trust, plus 40,513 shares held directly and 166 shares held indirectly by a spouse.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, through family trusts exercised 9,500 stock options at $135.42 and sold 9,500 shares of common stock on August 3, 2026 at weighted-average prices between $514.83 and $518.61, under a pre-arranged 10b5-1 trading plan adopted November 7, 2025. After the exercise, a family trust held 217,910 options expiring March 15, 2027, while Rothblatt held 40,513 shares directly and 166 shares indirectly via a spouse.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.4200 per share on July 31, 2026, acquiring 9,500 common shares. The trusts then sold 9,500 shares that day in multiple reported transactions at weighted-average prices, all under a pre-arranged 10b5-1 trading plan adopted November 7, 2025. After the exercise, a family trust continued to hold 227,410 options, while Rothblatt also held 40,513 shares directly and 166 shares indirectly through her spouse, plus additional holdings in family trusts.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts where she shares investment power, exercised 9,500 stock options at a strike price of $135.42 to acquire the same number of common shares, then sold 9,500 shares in several open-market or private transactions at weighted average prices in the low $520s per share. The option exercise and related sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of exercising 1,734,410 stock options expiring March 15, 2027 or December 31, 2026.

United Therapeutics Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share into common stock and, on July 29, 2026, sold the resulting 9,500 shares in multiple open-market transactions under a pre-arranged 10b5-1 trading plan adopted November 7, 2025.

After this exercise, a family trust reported holding 246,410 stock options expiring March 15, 2027, while Rothblatt also reported 40,513 shares held directly and 166 shares held indirectly through a spouse, along with additional share holdings in family trusts.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.4200 per share and received 9,500 common shares, then sold 9,500 shares in multiple transactions on 2026-07-28. The trades were executed under a pre-arranged 10b5-1 trading plan adopted November 7, 2025 that covers up to 1,734,410 options expiring March 15, 2027. Following the exercise, a family trust holds 255,910 options, and Rothblatt reports 40,513 shares directly and 166 shares indirectly via her spouse, along with additional family-trust holdings.

United Therapeutics Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 and acquired 9,500 common shares on July 27, 2026. Those shares were then sold in multiple trades totaling 9,500 shares at prices between about $526 and $535 per share under a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. Following the exercise, a trust reports 265,410 options remaining, as part of up to 1,734,410 options covered by the plan and expiring March 15, 2027, while separate entries show 40,513 shares held directly and 166 shares held indirectly by spouse.

United Therapeutics Chairperson & CEO Martine A. Rothblatt reported that family trusts with which she shares investment power exercised 9,500 stock options at an exercise price of $135.42 per share and sold 9,500 shares of common stock on July 24, 2026 at weighted-average prices between approximately $528 and $535 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.

Following the exercise, the trusts continue to hold 274,910 stock options from this grant expiring March 15, 2027, and Rothblatt also directly owns 40,513 common shares. The trading plan will continue until the earlier of the exercise of up to 1,734,410 stock options or December 31, 2026.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 per share into common stock on 2026-07-23 and sold the resulting 9,500 shares in multiple transactions at prices between $522.31 and $531.94 per share.

The options, expiring March 15, 2027, are covered by a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025, which continues until the earlier of exercising 1,734,410 options or December 31, 2026. After this exercise, 284,410 options remain held indirectly by a family trust, and Rothblatt also holds 40,513 shares directly and 166 shares indirectly through a spouse.

United Therapeutics Corporation director Victor J. Dzau reported equity awards received on July 22, 2026 in connection with his appointment to the Board. He was granted 730 restricted stock units and 2,300 stock options under the Non-Employee Director Compensation Program. Each RSU represents one share of common stock upon vesting. The stock options cover common stock at an exercise price of $527.0700 per share, vest on the one-year anniversary of the grant date, and expire on July 22, 2033.

United Therapeutics granted director Linda Maxwell annual non-employee director equity awards on 2026-07-22, consisting of 380 restricted stock units and 1,190 stock options on common stock. The options carry a $527.0700 exercise price and expire on 2033-07-22.

Each restricted stock unit represents one share of common stock after vesting and has no expiration date. Both awards become fully vested on the earlier of one year from grant or the anticipated June 25, 2027 Annual Meeting of Shareholders. No sales or dispositions were reported.

United Therapeutics Corporation director Tommy G Thompson received equity compensation on July 22, 2026, consisting of 380 restricted stock units and 1,190 stock options with an exercise price of $527.07 per share.

The awards, described as an annual non-employee director grant, vest on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, with June 25, 2027 noted as the anticipated meeting date. Each restricted stock unit represents the right to receive one share of common stock after vesting and has no expiration date.

After these awards, Thompson holds 8,480 United Therapeutics common shares directly (including 880 issued from previously deferred RSUs), plus 8,200 shares held indirectly by a trust and 5,800 shares held indirectly through a family LLC.

Tracey Kevin reported acquisition or exercise transactions in this Form 4 filing.

United Therapeutics Corporation director Kevin Tracey reported an annual non-employee director equity award of 760 restricted stock units (RSUs) on July 22, 2026. Each RSU represents the right to receive, following vesting, one share of United Therapeutics common stock.

The RSUs become fully vested on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. Following this grant, Tracey directly holds 760 RSUs, and the units have no stated expiration date.

Olian Judy D. reported acquisition or exercise transactions in this Form 4 filing.

United Therapeutics Corporation director Judy D. Olian received an annual non-employee director equity award of 760 restricted stock units (RSUs) on July 22, 2026. Each RSU entitles her to one share of common stock after vesting, with full vesting on the earlier of the one-year anniversary of grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. Following this award, she holds 760 RSUs and 5,555 shares of common stock directly. The RSUs have no expiration date.

United Therapeutics director Jan Malcolm received equity compensation grants. On July 22, 2026, Malcolm was granted 380 restricted stock units and stock options for 1,190 shares of common stock at an exercise price of $527.07, as annual non-employee director awards. These awards vest on the earlier of the one-year anniversary of the grant date or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. Following the grants, Malcolm directly holds 380 RSUs, 3,570 stock options and 450 common shares. The awards were reported as made pursuant to a Rule 10b5-1 trading arrangement.

United Therapeutics Corporation director Nilda Mesa received annual non-employee director equity awards on July 22, 2026, consisting of 380 restricted stock units and 1,190 stock options. Each restricted stock unit represents the right to receive one common share upon vesting. The options carry a $527.0700 exercise price and, together with the RSUs, are scheduled to become fully vested on the earlier of the one-year anniversary of the grant date or the next Annual Meeting of Shareholders, anticipated for June 25, 2027. After these awards, Mesa directly holds 5,678 shares of United Therapeutics common stock.

United Therapeutics Corp director Louis W. Sullivan received an annual non-employee director stock option award covering 2,380 shares of common stock at an exercise price of $527.07 per share. The options vest on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027, and expire on July 22, 2033. After this filing, he holds 2,983 common shares directly and 1,457 shares indirectly through a trust over which he has sole investment and voting power; totals were updated to correct a prior underreporting of 590 trust shares.

United Therapeutics Corp director Christopher Causey received an annual non-employee director stock option award covering 2,380 shares of common stock at a $527.07 exercise price, expiring July 22, 2033. The options become fully vested on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. Following this grant, he directly holds 4,190 common shares and options on 2,380 shares.

United Therapeutics director Christopher Patusky received a grant of 2,380 stock options on July 22, 2026, with an exercise price of $527.07 per share, expiring July 22, 2033. This annual non-employee director award becomes fully vested on the earlier of the one-year anniversary of the grant date or the date of the next Annual Meeting of Shareholders, which is anticipated to be June 25, 2027. Following the grant, he directly holds 2,380 options under this award and 2,410 shares of common stock.

Giltner Richard reported acquisition or exercise transactions in this Form 4 filing.

United Therapeutics Corp director Richard Giltner received an annual non-employee director award of 760 restricted stock units, each representing one share of common stock upon vesting.

The RSUs vest on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. After this award he holds 760 RSUs and 21,884 common shares directly.

United Therapeutics Corp director Ray Kurzweil received annual equity awards consisting of 380 restricted stock units and 1,190 stock options on July 22, 2026. The awards vest in full on the earlier of the one-year anniversary of the grant or the next Annual Meeting, anticipated on June 25, 2027. The options carry an exercise price of $527.07 per share and expire on July 22, 2033. Following these awards, he directly holds 13,320 shares of United Therapeutics common stock. The restricted stock units have no expiration date and each converts into one share upon vesting.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 per share into common stock on July 22, 2026 and sold 9,500 shares in multiple trades at weighted-average prices reported from $524.27 to $539.47 per share. These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027 or December 31, 2026. Following the exercise, family trusts held 293,910 stock options, while Rothblatt also reported 40,513 common shares held directly and 166 shares held indirectly through a spouse.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at $135.42 on July 21, 2026, acquiring 9,500 common shares, then sold 9,500 shares in multiple open-market trades at weighted-average prices between $523.81 and $537.13. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027 or December 31, 2026. Following this option exercise, a family trust holds 303,410 stock options, while Rothblatt also directly owns 40,513 common shares and has additional indirect holdings including 166 shares held by a spouse.

United Therapeutics Chairperson & CEO Martine Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 per share into common stock on July 20, 2026, then sold an equal 9,500 shares in multiple open-market trades. The transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which permits the exercise of up to 1,734,410 options expiring March 15, 2027, or runs until December 31, 2026. After this exercise, a family trust continues to hold 312,910 stock options, while Rothblatt also holds 40,513 common shares directly and 166 shares indirectly via her spouse.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, reported an exercise-and-sale sequence involving company stock on July 17, 2026. Family trusts associated with the reporting person exercised 9,500 stock options at $135.42 per share and sold 9,500 common shares across 11 transactions at weighted-average prices ranging from $528.39 to $542.49.

All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options (expiring March 15, 2027) or December 31, 2026. After the reported trades, family trusts and related indirect holdings reported 324,443 common shares and 322,410 stock options remaining.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share on July 16, 2026, and on the same date sold 9,500 shares of common stock in multiple trades, including a tranche at a weighted average price of $530.1449 per share. These option exercises and sales were carried out by a family trust under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027, or December 31, 2026. After these transactions, that family trust held 324,443 shares of United Therapeutics common stock, while Rothblatt also reported 40,513 shares held directly and 331,910 stock options held in a family trust.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt, through family trusts and personal accounts, exercised stock options for 9,500 shares at $135.4200 per share and sold 9,500 shares of common stock in multiple open-market trades at prices between $520.9158 and $534.2733 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which allows for the potential exercise of up to 1,734,410 stock options expiring March 15, 2027, or terminates by December 31, 2026.

United Therapeutics EVP & General Counsel Paul A. Mahon exercised stock options for 8,300 shares of common stock at $146.03 per share and sold 8,300 shares in multiple open-market trades at prices between $527.5950 and $536.8526. These trades were executed under a pre-arranged Rule 10b5-1 plan entered into on August 11, 2025, and Mahon continues to hold 80,740 stock options afterward.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.4200 per share and on the same date sold 9,500 common shares in multiple open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 40,513 common shares directly and also maintains additional common stock and stock options through family trusts and her spouse.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at $135.4200 per share and sold 9,500 shares in open-market trades on July 13, 2026, with reported prices including $542.8000 and $533.7022 per share. The exercise and sales were carried out under a pre-arranged 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 stock options expiring March 15, 2027 or December 31, 2026. After these transactions, Rothblatt holds 40,513 shares directly, plus additional indirect common stock and stock option positions in family trusts and a spouse account, including stock options over 349,192 underlying shares at a $135.4200 exercise price expiring March 15, 2027.

UNITED THERAPEUTICS Corp director Richard Giltner reported the vesting of equity compensation and related share issuance. On July 9, 2026, 1,310 restricted stock units vested and converted on a one-for-one basis into 1,310 shares of common stock. Following this RSU vesting and conversion, Giltner holds 21,884 shares of common stock directly. The restricted stock units had no expiration date and were converted at a price of $0.00 per unit, reflecting non-cash equity compensation rather than an open-market purchase or sale.